MD Anderson Cancer Center researchers have identified recent developments in effective combination therapies for patients with BRAF V600E mutations, an approach to identify cancer biomarkers in extracellular vesicles, therapeutic strategies for improving treatment responses in non-small cell lung cancer, and a novel combination therapy to overcome treatment resistance in a subset of patients with acute myeloid leukemia.
Adults aged 80 and older with early-stage lung cancer can safely undergo surgery and achieve outcomes comparable to younger patients, challenging longstanding assumptions about age and cancer treatment, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center.
